BerGenBio ASA (BRRGF)

BerGenBio ASA (BRRGF) Healthcare & Pipeline Overview

BerGenBio ASA is a Norwegian clinical-stage biopharmaceutical company specializing in AXL inhibitor development for immune-evasive cancers and respiratory diseases. With its lead candidate Bemcentinib in Phase II trials for multiple indications, including non-small cell lung cancer and acute myeloid leukemia, and a collaboration with Merck & Co., the company targets significant unmet medical needs within the biotechnology sector.

What Is the Investment Thesis for BRRGF?

BerGenBio ASA presents a research-grade investment thesis centered on its clinical-stage pipeline targeting AXL, a critical mediator in cancer and viral diseases. The company's lead candidate, Bemcentinib, a small molecule AXL inhibitor, is in Phase II trials for significant indications like non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome, and COVID-19. Successful advancement through these trials, particularly with positive efficacy and safety data, represents a primary value driver. The ongoing collaboration with Merck & Co. for clinical trials further validates its scientific approach and provides potential for accelerated development and market access. Financially, the company currently operates with a negative profit margin of -1990.4%, typical for a clinical-stage biotech, and a gross margin of 98.1%, reflecting its R&D-heavy cost structure. With a market capitalization of $9.49B, the valuation is heavily reliant on future clinical successes and potential commercialization. The company's beta of 1.31 indicates higher volatility compared to the broader market, consistent with the inherent risks of biopharmaceutical development. Key catalysts include data readouts from ongoing Phase II trials and potential expansion of the Merck collaboration, while risks encompass clinical trial failures, regulatory hurdles, and the need for significant future funding.

Based on FMP financials and quantitative analysis

BRRGF Key Highlights

• Market capitalization stands at $9.49 billion, reflecting investor expectations for its clinical-stage pipeline.
• Gross margin of 98.1% indicates a high-value intellectual property and R&D-focused operational model, typical for a biotechnology company prior to commercialization.
• Profit margin is -1990.4%, consistent with a clinical-stage biopharmaceutical company heavily investing in research and development without significant product revenue.
• Bemcentinib, the lead drug candidate, is in Phase II clinical development for multiple cancer indications and COVID-19, representing significant pipeline progress.
• A strategic collaboration agreement with Merck & Co. for clinical trials underscores external validation and potential for future development acceleration.

Who Are BRRGF's Competitors?

BRRGF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BRRGF's Key Strengths?

• Lead candidate Bemcentinib in Phase II clinical development for multiple significant cancer indications and COVID-19, demonstrating broad potential.
• Strategic collaboration agreement with Merck & Co. provides external validation and potential for accelerated development.
• Specialized focus on AXL inhibition, a mechanism implicated in immune evasion and drug resistance, addressing critical unmet medical needs.
• Pipeline includes both a small molecule (Bemcentinib) and an antibody (tilvestamab) targeting AXL, offering diverse therapeutic approaches.
• High gross margin of 98.1% indicates the inherent value of its intellectual property and R&D focus.

What Are BRRGF's Weaknesses?

• Operating with a significant negative profit margin (-1990.4%), typical for a clinical-stage biotech, indicating reliance on external funding.
• Small employee base of 13, which may limit the breadth of internal capabilities and necessitate reliance on external partners.
• Clinical-stage status means no commercialized products and thus no product-based revenue generation currently.
• High beta of 1.31 suggests higher stock price volatility, which can be a concern for some investors.
• The success of the company is heavily concentrated on the successful development and approval of a limited number of drug candidates.

What Could Drive BRRGF Stock Higher?

• Positive data readouts from ongoing Phase II clinical trials for Bemcentinib in non-small cell lung cancer (NSCLC), acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS).
• Advancement of Bemcentinib into Phase III clinical trials for any of its current indications, signaling significant progress towards regulatory approval.
• Announcement of new or expanded strategic partnerships or licensing agreements for Bemcentinib or tilvestamab, potentially providing additional funding or market access.
• Continued progress in the Phase II clinical development of Bemcentinib for COVID-19, with potential for emergency use authorization or accelerated approval.
• Further development and data generation from the Phase Ib clinical trial for tilvestamab, demonstrating its safety and preliminary efficacy.

What Are the Key Risks for BRRGF?

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or unexpected adverse events for Bemcentinib or tilvestamab could lead to delays, increased costs, or discontinuation of development.
• Significant negative profit margin (-1990.4%) indicates a continuous need for substantial capital raises, posing potential dilution risks for existing shareholders.
• Intense competition in the oncology and antiviral therapeutic areas from larger, more established pharmaceutical companies with greater resources.
• Regulatory hurdles and lengthy approval processes inherent to biopharmaceutical development could delay market entry and commercialization of drug candidates.
• Dependence on the successful execution and outcomes of the collaboration agreement with Merck & Co., with any changes potentially impacting development timelines and funding.

What Are the Growth Opportunities for BRRGF?

• **Advancement of Bemcentinib in Non-Small Cell Lung Cancer (NSCLC)**: Bemcentinib is currently in Phase II clinical development for NSCLC, a leading cause of cancer-related deaths globally. The NSCLC market is substantial, projected to reach over $40 billion by the mid-2030s, driven by increasing incidence and demand for more effective, targeted therapies. Positive data from these trials could significantly de-risk the asset and attract further investment or partnership opportunities, potentially leading to accelerated development pathways and market entry within the next 5-7 years, assuming successful Phase III and regulatory approval.
• **Expansion into Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)**: BerGenBio's lead candidate, Bemcentinib, is also being evaluated in Phase II trials for AML and MDS, severe hematological malignancies with limited treatment options. The global AML market is anticipated to exceed $6 billion by 2030, while the MDS market is also growing. Successful clinical outcomes in these indications could open up additional significant market segments for BerGenBio, diversifying its therapeutic reach and revenue potential within the next 7-10 years, contingent on clinical and regulatory success.
• **Potential for COVID-19 Treatment with Bemcentinib**: The ongoing Phase II clinical development of Bemcentinib for COVID-19 represents a timely growth opportunity. While vaccine development has progressed, there remains a critical need for effective antiviral and anti-inflammatory treatments for severe COVID-19 cases and long COVID. The global market for COVID-19 therapeutics continues to evolve, with significant demand for new mechanisms of action. Positive results could position Bemcentinib as a valuable therapeutic option, potentially offering a faster path to market given the public health urgency, possibly within the next 2-4 years.
• **Development of Tilvestamab (Anti-AXL Antibody)**: The company's pipeline includes tilvestamab, an anti-AXL antibody, currently in Phase Ib clinical trials. This represents a distinct therapeutic modality targeting AXL, potentially offering advantages in specific patient populations or disease contexts compared to small molecule inhibitors. Advancing tilvestamab through clinical development could broaden BerGenBio's AXL-targeting franchise and intellectual property portfolio. The market for antibody-based therapies is robust and growing, with global sales exceeding $150 billion annually. Successful progression could yield a new revenue stream within 8-12 years.
• **Leveraging the Merck & Co. Collaboration**: BerGenBio's collaboration agreement with Merck & Co. for clinical trials is a significant strategic asset. This partnership provides access to Merck's extensive resources, expertise, and potentially accelerates clinical development and regulatory pathways. Successful milestones or expansion of this collaboration could lead to co-development agreements, licensing deals, or even acquisition, providing substantial non-dilutive funding or market access. This collaboration could significantly impact the timeline and scale of market penetration for BerGenBio's assets, with potential benefits materializing over the next 3-7 years.

What Opportunities Does BRRGF Have?

• Successful advancement of Bemcentinib through Phase II and into Phase III trials, leading to potential regulatory approval and commercialization.
• Expansion of the collaboration with Merck & Co. or formation of new strategic partnerships for co-development or regional licensing.
• Positive data readouts from ongoing clinical trials, particularly for high-impact indications like NSCLC and AML, driving increased investor interest and valuation.
• Potential for Bemcentinib to become a key therapeutic option for COVID-19 or other respiratory diseases, addressing an ongoing global health need.
• Broadening the AXL inhibitor platform to explore additional indications or develop next-generation compounds.

What Threats Does BRRGF Face?

• Clinical trial failures or unexpected adverse events during ongoing or future development, leading to delays or discontinuation of drug candidates.
• Intense competition from larger pharmaceutical companies and other biotechnology firms developing oncology and antiviral treatments.
• Regulatory hurdles and lengthy approval processes, which can significantly delay market entry and increase development costs.
• Inability to secure sufficient future funding to support ongoing clinical trials and research and development activities.
• Patent challenges or expiration, potentially leading to generic or biosimilar competition once drugs are approved and commercialized.

What Are BRRGF's Competitive Advantages?

• Proprietary AXL inhibitor platform: BerGenBio's specialized focus on AXL inhibition provides a distinct therapeutic approach for targeting immune evasion and drug resistance in cancer, differentiating it from broader oncology pipelines.
• Clinical trial progress: With Bemcentinib in Phase II for multiple significant indications and tilvestamab in Phase Ib, the company has established a clinical lead in AXL-targeting therapies, creating a barrier to entry for new competitors.
• Strategic collaboration with Merck & Co.: This partnership provides external validation, access to significant resources, and potential for accelerated development, enhancing credibility and market reach.
• Intellectual property: Development of novel small molecules and antibodies targeting AXL suggests a robust patent portfolio protecting its drug candidates and their therapeutic applications.
• Deep scientific expertise: A focused team with specialized knowledge in AXL biology and drug development provides a competitive edge in optimizing and advancing its pipeline.

What Does BRRGF Do?

BerGenBio ASA, incorporated in 2007 and headquartered in Bergen, Norway, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel medicines. The company's core focus is on addressing significant unmet medical needs in immune-evasive, drug-resistant, and metastatic cancers, alongside respiratory diseases. Its scientific foundation is built upon the understanding and targeting of AXL, a receptor tyrosine kinase implicated in various biological processes, including cancer progression, immune evasion, and viral infections. BerGenBio's lead drug candidate is Bemcentinib, a highly bio-available small molecule AXL inhibitor. This compound is currently undergoing extensive Phase II clinical development across multiple major cancer indications, including non-small cell lung cancer (NSCLC), acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS). Furthermore, Bemcentinib is also being evaluated in Phase II trials for its potential application in treating COVID-19, highlighting the broad therapeutic potential of AXL inhibition. Beyond Bemcentinib, the company is advancing another promising candidate, tilvestamab, an anti-AXL antibody, which is in Phase Ib clinical trials. BerGenBio ASA has strategically formed a collaboration agreement with Merck & Co. for clinical trials, a partnership that underscores the potential and strategic importance of its drug pipeline. The company operates with a lean team of 13 employees, focusing its resources on research and development to bring its innovative therapies to market. Its evolution since 2007 has been marked by a consistent commitment to advancing its AXL inhibitor platform, positioning itself as a specialized player in the competitive biopharmaceutical landscape with a clear focus on challenging diseases.

What Products and Services Does BRRGF Offer?

• Develops drugs to treat immune-evasive, drug-resistant, and metastatic cancers.
• Engages in the development of therapies for respiratory diseases, including COVID-19.
• Focuses on AXL inhibition, a biological pathway critical in cancer progression and viral infections.
• Conducts Phase II clinical trials for Bemcentinib, its lead small molecule AXL inhibitor, in various cancer indications.
• Evaluates Bemcentinib in Phase II clinical trials for the treatment of COVID-19.
• Advances tilvestamab, an anti-AXL antibody, through Phase Ib clinical trials.
• Collaborates with Merck & Co. on clinical trials for its drug candidates.
• Operates as a clinical-stage biopharmaceutical company, primarily focused on research and development.

How Does BRRGF Make Money?

• Primarily generates revenue through strategic collaboration agreements and potential milestone payments from pharmaceutical partners, such as the existing agreement with Merck & Co.
• Relies on capital raises, including equity financing, to fund extensive research and development activities, clinical trials, and operational expenses.
• Aims for future revenue generation through the successful commercialization and sales of its proprietary drug candidates, Bemcentinib and tilvestamab, upon regulatory approval.
• Potentially seeks licensing agreements or out-licensing opportunities for its drug candidates in specific territories or indications to maximize market reach and profitability.
• Invests heavily in intellectual property protection, including patents, to secure exclusive rights to its AXL inhibitor platform and drug candidates.

What Industry Does BRRGF Operate In?

BerGenBio ASA operates within the highly specialized and competitive biotechnology industry, a sub-sector of Healthcare. The company's focus on AXL inhibition positions it within the oncology and infectious disease therapeutic areas, which are characterized by significant unmet medical needs and substantial market potential. The broader biotechnology market is driven by advancements in genomic research, targeted therapies, and personalized medicine, with a continuous demand for innovative solutions for complex diseases like cancer. BerGenBio's clinical-stage status means it is primarily engaged in research and development, aiming to bring novel drugs through rigorous regulatory pathways. The competitive landscape includes numerous established pharmaceutical giants and smaller biotech firms also developing oncology and antiviral treatments. Success in this industry is heavily dependent on clinical trial outcomes, intellectual property protection, and strategic partnerships. BerGenBio's AXL inhibitor platform aims to differentiate it by targeting a mechanism implicated in immune evasion and drug resistance, addressing a critical challenge in cancer therapy.

Who Are BRRGF's Key Customers?

• Future patients suffering from non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome, and other immune-evasive cancers.
• Individuals affected by respiratory diseases, including those with COVID-19, who may benefit from novel therapeutic interventions.
• Oncologists, hematologists, and infectious disease specialists who would prescribe BerGenBio's approved therapies.
• Global healthcare systems, hospitals, and clinics that would procure and administer the company's drugs.
• Pharmaceutical companies seeking strategic partnerships, licensing opportunities, or co-development agreements for innovative oncology and antiviral assets.

FY2026 estForward Outlook

Wall Street analysts project BerGenBio ASA revenue of about $35.9M for fiscal 2026, with EPS near $-0.69.

Quarterly Financial Performance: BerGenBio ASA

Revenue for BerGenBio ASA came in at $2.4M during Q2 2025. The company recorded a net loss of $27.1M, with diluted EPS of $-0.69. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare.

BRRGF Valuation & Market Position

With a $9.49B market cap, BerGenBio ASA sits in the mid-cap segment of the market. Relative to its peer group, BRRGF's quantitative score of 74/100 is roughly in line with the peer average of 77/100.

Key Financial Metrics

Return on assets is -76.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -56.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.23 indicates the company holds enough short-term assets to cover its near-term obligations.

F-Score 2/9Financial Health

BerGenBio ASA's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Company Profile

BerGenBio ASA operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Bergen, NO. The company is led by CEO Oystein Soug. BRRGF has traded publicly since 2018.

BRRGF Financials

BRRGF Latest News

No recent news available for BRRGF.

BRRGF Analyst Consensus

BRRGF MoonshotScore

What Investors Ask About BerGenBio ASA (BRRGF) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources